Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 11;18(7):1032.
doi: 10.3390/ph18071032.

Charged Thienobenzo-1,2,3-Triazoles as Especially Potent Non-Selective Cholinesterase Inhibitors: Design, Anti-Inflammatory Activity, and Computational Study

Affiliations

Charged Thienobenzo-1,2,3-Triazoles as Especially Potent Non-Selective Cholinesterase Inhibitors: Design, Anti-Inflammatory Activity, and Computational Study

Antonija Jelčić et al. Pharmaceuticals (Basel). .

Abstract

Background/Objectives: This research reports the synthesis and evaluation of novel charged thienobenzo-triazoles as non-selective cholinesterase inhibitors (AChEs and BChEs), their anti-inflammatory properties, and a computational study. Methods: Fifteen derivatives were created through photochemical cyclization and quaternization of the triazole core. The compounds were tested for AChE and BChE inhibition. They showed greater potency and selectivity toward BChE. Results: The most potent compound, derivative 14, inhibited BChE with an IC50 of 98 nM, while derivative 9 also displayed significant anti-inflammatory activity by inhibiting LPS-induced TNF-α production (IC50 = 0.66 µM). Molecular docking revealed that triazolinium salts form key π-π and electrostatic interactions within enzyme active sites. In silico predictions indicated favorable ADME-Tox properties for compounds 9 and 11, including low mutagenicity and moderate CNS permeability. Conclusions: These findings highlight the potential of new charged triazolinium salts as peripherally selective cholinesterase inhibitors with additional anti-inflammatory potential.

Keywords: ADME-Tox prediction; BChE inhibitors; anti-inflammatory activity; cholinesterase; molecular docking; thienobenzo-1,2,3-triazoles.

PubMed Disclaimer

Conflict of interest statement

The authors Paula Pongrac, Dora Štefok, and Martina Bosnar were employed by the company Selvita Ltd. Zlata Lasić is employed by the Pliva Hrvatska d.o.o. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Structures of uncharged thienobenzo-triazoles I with preferred inhibition of BChE and their charged triazolinium salts II as dual cholinesterase inhibitors [19].
Scheme 1
Scheme 1
Synthetic steps to charged triazolinium benzyl salts 115.
Figure 2
Figure 2
Structures of new charged thienobenzo-1,2,3-triazolinium salts 115 and their isolated yields in brackets.
Figure 3
Figure 3
Parts of the 1H NMR spectra of charged triazolinium salts (a) 9, (b) 11, and (c) 1.
Figure 4
Figure 4
Inhibition of LPS-stimulated TNFα production in PBMCs from two donors for charged triazolinium bromide salt 9.
Figure 5
Figure 5
(a) The structure of triazolinium salt 9 docked into the active site of AChE. (b) Structure of triazolinium salt 11 docked into the active site of AChE. Ligands are presented using a ball-and-stick model, with distances given in angstroms.
Figure 6
Figure 6
(a) The structure of triazolinium salt 9 docked into the active site of BChE. (b) Structure of triazolinium salt 11 docked into the active site of BChE. Ligands are presented using a ball-and-stick model, with distances given in angstroms.

Similar articles

Cited by

References

    1. Masson P., Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: Catalytic complexities and therapeutic promises. Arch. Biochem. Biophys. 2010;15:107–120. doi: 10.1016/j.abb.2009.12.005. - DOI - PMC - PubMed
    1. Colović M.B., Krstić D.Z., Lazarević-Pašti T.D., Bondžić A.M., Vasić V.M. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr. Neuropharmacol. 2013;11:315–335. doi: 10.2174/1570159X11311030006. - DOI - PMC - PubMed
    1. Anand P., Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch. Pharmacal Res. 2013;36:375–399. doi: 10.1007/s12272-013-0036-3. - DOI - PubMed
    1. Talesa V.N. Acetylcholinesterase in Alzheimer’s disease. Curr. Drug Targets. 2001;2:363–373. doi: 10.1016/S0047-6374(01)00309-8. - DOI
    1. Greig N.H., Utsuki T., Yu Q.S., Holloway H.W. A new therapeutic target in Alzheimer’s disease treatment: Selective butyrylcholinesterase inhibition. Curr. Med. Chem. 2005;12:237–243.

LinkOut - more resources